Nuvo Research (TSX:NRI) has received Health Canada approval to conduct a new Phase 2 clinical trial to assess WF10 for the treatment of allergic rhinitis.
The 2015 WF10 Trial will begin this month. It will be a randomized, double-blind, placebo-controlled, single-center trial to assess the efficacy, safety and tolerability of a regimen of five WF10 infusions.
The trial will enroll about 146 patients who have a moderate-to-severe allergy to grass and ragweed pollen and will build on previous WF10 allergic rhinitis studies run in 2010 and 2014. Topline results should be available in the fourth quarter this year or early in the first quarter of 2016.
Patients’ symptoms have already been recorded in an Environmental Exposure Chamber (EEC), and will be recorded in the field during the grass and ragweed allergy seasons and again in the EEC after completion of the ragweed season. The trial will be conducted in southern Ontario, Canada by Inflamax Research.
In a statement, Dr. Henrich Guntermann, president, Europe & Immunology Group, said the design of the new study includes a number of features that differentiate it from the inconclusive 2014 WF10 Trial to enhance the chance of a successful outcome.
